Light-controlled inhibition of BRAFV600E kinase
Standard
Light-controlled inhibition of BRAFV600E kinase. / Hoorens, Mark W H; Ourailidou, Maria E; Rodat, Theo; van der Wouden, Petra E; Kobauri, Piermichele; Kriegs, Malte; Peifer, Christian; Feringa, Ben L; Dekker, Frank J; Szymanski, Wiktor.
in: EUR J MED CHEM, Jahrgang 179, 01.10.2019, S. 133-146.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Light-controlled inhibition of BRAFV600E kinase
AU - Hoorens, Mark W H
AU - Ourailidou, Maria E
AU - Rodat, Theo
AU - van der Wouden, Petra E
AU - Kobauri, Piermichele
AU - Kriegs, Malte
AU - Peifer, Christian
AU - Feringa, Ben L
AU - Dekker, Frank J
AU - Szymanski, Wiktor
N1 - Copyright © 2019 Elsevier Masson SAS. All rights reserved.
PY - 2019/10/1
Y1 - 2019/10/1
N2 - Metastatic melanoma is amongst the most difficult types of cancer to treat, with current therapies mainly relying on the inhibition of the BRAFV600E mutant kinase. However, systemic inhibition of BRAF by small molecule drugs in cancer patients results - paradoxically - in increased wild-type BRAF activity in healthy tissue, causing side-effects and even the formation of new tumors. Here we show the development of BRAFV600E kinase inhibitors of which the activity can be switched on and off reversibly with light, offering the possibility to overcome problems of systemic drug activity by selectively activating the drug at the desired site of action. Based on a known inhibitor, eight photoswitchable effectors containing an azobenzene photoswitch were designed, synthesized and evaluated. The most promising inhibitor showed an approximately 10-fold increase in activity upon light-activation. This research offers inspiration for the development of therapies for metastatic melanoma in which tumor tissue is treated with an active BRAFV600E inhibitor with high spatial and temporal resolution, thus limiting the damage to other tissues.
AB - Metastatic melanoma is amongst the most difficult types of cancer to treat, with current therapies mainly relying on the inhibition of the BRAFV600E mutant kinase. However, systemic inhibition of BRAF by small molecule drugs in cancer patients results - paradoxically - in increased wild-type BRAF activity in healthy tissue, causing side-effects and even the formation of new tumors. Here we show the development of BRAFV600E kinase inhibitors of which the activity can be switched on and off reversibly with light, offering the possibility to overcome problems of systemic drug activity by selectively activating the drug at the desired site of action. Based on a known inhibitor, eight photoswitchable effectors containing an azobenzene photoswitch were designed, synthesized and evaluated. The most promising inhibitor showed an approximately 10-fold increase in activity upon light-activation. This research offers inspiration for the development of therapies for metastatic melanoma in which tumor tissue is treated with an active BRAFV600E inhibitor with high spatial and temporal resolution, thus limiting the damage to other tissues.
U2 - 10.1016/j.ejmech.2019.06.042
DO - 10.1016/j.ejmech.2019.06.042
M3 - SCORING: Journal article
C2 - 31252305
VL - 179
SP - 133
EP - 146
JO - EUR J MED CHEM
JF - EUR J MED CHEM
SN - 0223-5234
ER -